A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma
| Autor: | Richard G. Knowles, William R. Ford, Kenneth J. Broadley, Emma Jane Kidd, Anthony T. Nials, Rhys L. Evans |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cyclopropanes
Male Pulmonary and Respiratory Medicine Time Factors Ovalbumin Guinea Pigs Administration Oral Aminopyridines Inflammation Sulfides Fluticasone propionate Administration Inhalation medicine Animals Pharmacology (medical) Anti-Asthmatic Agents Roflumilast Asthma biology Inhalation business.industry Biochemistry (medical) respiratory system Eosinophil medicine.disease respiratory tract diseases Androstadienes Disease Models Animal medicine.anatomical_structure Acute Disease Benzamides Chronic Disease Immunology biology.protein Fluticasone Bronchoconstriction Bronchial Hyperreactivity medicine.symptom business Histamine medicine.drug |
| Zdroj: | Pulmonary Pharmacology & Therapeutics. 25:453-464 |
| ISSN: | 1094-5539 |
| Popis: | Pre-clinical evaluation of asthma therapies requires animal models of chronic airways inflammation, airway hyperresponsiveness (AHR) and lung remodelling that accurately predict drug effectiveness in human asthma. However, most animal models focus on acute allergen challenges where chronic inflammation and airway remodelling are absent. Chronic allergen challenge models have been developed in mice but few studies use guinea-pigs which may be more relevant to humans. We tested the hypothesis that a chronic rather than acute pulmonary inflammation model would best predict clinical outcome for asthma treatments. Guinea-pigs sensitized with ovalbumin (OVA) received single (acute) or nine OVA inhalation challenges at 48 h intervals (chronic). Airways function was recorded as specific airways conductance (sG(aw)) in conscious animals for 12 h after OVA challenge. AHR to inhaled histamine, inflammatory cell influx and lung histology were determined 24 h after the single or 9th OVA exposure. The inhaled corticosteroid, fluticasone propionate (FP), the phosphodiesterase 4 inhibitor, roflumilast, and the inducible nitric oxide synthase (iNOS) inhibitor, GW274150, orally, were administered 24 and 0.5 h before and 6 h after the single or final chronic OVA exposure. Both models displayed early (EAR) and late (LAR) asthmatic responses to OVA challenge, as falls in sG(aw), AHR, as increased histamine-induced bronchoconstriction, and inflammatory cell influx. Tissue remodelling, seen as increased collagen and goblet cell hyperplasia, occurred after multiple OVA challenge. Treatment with FP and roflumilast inhibited the LAR, cell influx and AHR in both models, and the remodelling in the chronic model. GW274150 also inhibited the LAR, AHR and eosinophil influx in the acute model, but not, together with the remodelling, in the chronic model. In the clinical setting, inhaled corticosteroids and phosphodiesterase 4 inhibitors are relatively effective against most features of asthma whereas the iNOS inhibitor GW274150 was ineffective. Thus, while there remain certain differences between our data and clinical effectiveness of these antiasthma drugs, a chronic pulmonary inflammation guinea-pig model does appear to be a better pre-clinical predictor of potential asthma therapeutics than an acute model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect